ADC Therapeutics SA (ADCT)

USD 1.21

(-0.82%)

Revenue Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual revenue in 2023 was 69.55 Million USD , down -66.86% from previous year.
ADC Therapeutics SA's latest quarterly revenue in 2024 Q2 was 17.41 Million USD , down -3.56% from previous quarter.
ADC Therapeutics SA reported a annual revenue of 209.9 Million USD in annual revenue 2022, up 518.89% from previous year.
ADC Therapeutics SA reported a annual revenue of 33.91 Million USD in annual revenue 2021, down 0.0% from previous year.
ADC Therapeutics SA reported a quarterly revenue of 17.41 Million USD for 2024 Q2, down -3.56% from previous quarter.
ADC Therapeutics SA reported a quarterly revenue of 19.28 Million USD for 2023 Q2, up 1.53% from previous quarter.

Annual Revenue Chart of ADC Therapeutics SA (2023 - 2017)

Historical Annual Revenue of ADC Therapeutics SA (2023 - 2017)

Year	Revenue	Revenue Growth
2023	69.55 Million USD	-66.86%
2022	209.9 Million USD	518.89%
2021	33.91 Million USD	0.0%
2020	- USD	-100.0%
2019	2.34 Million USD	105.26%
2018	1.14 Million USD	-36.77%
2017	1.8 Million USD	0.0%

Year	Revenue	Revenue Growth
2024 Q1	18.05 Million USD	7.52%
2024 Q2	17.41 Million USD	-3.56%
2023 Q2	19.28 Million USD	1.53%
2023 Q3	14.49 Million USD	-24.84%
2023 Q1	18.99 Million USD	-72.79%
2023 FY	69.55 Million USD	-66.86%
2023 Q4	16.79 Million USD	15.85%
2022 Q4	69.79 Million USD	-8.55%
2022 Q3	76.32 Million USD	341.39%
2022 Q2	17.29 Million USD	-62.81%
2022 FY	209.9 Million USD	518.89%
2022 Q1	46.49 Million USD	173.36%
2021 FY	33.91 Million USD	0.0%
2021 Q3	13.14 Million USD	249.65%
2021 Q1	- USD	-100.0%
2021 Q4	17.01 Million USD	29.38%
2021 Q2	3.76 Million USD	0.0%
2020 Q1	- USD	0.0%
2020 FY	- USD	-100.0%
2020 Q2	- USD	0.0%
2020 Q3	- USD	0.0%
2020 Q4	51.9 Million USD	0.0%
2019 Q4	- USD	0.0%
2019 Q3	- USD	-100.0%
2019 Q2	1.96 Million USD	67.69%
2019 Q1	1.17 Million USD	354.37%
2019 FY	2.34 Million USD	105.26%
2018 Q3	257.5 Thousand USD	-17.6%
2018 Q2	312.5 Thousand USD	0.0%
2018 FY	1.14 Million USD	-36.77%
2018 Q1	312.5 Thousand USD	0.0%
2018 Q4	257.5 Thousand USD	0.0%
2017 FY	1.8 Million USD	0.0%

Peer Revenue Comparison of ADC Therapeutics SA

Name	Revenue	Revenue Difference
Alto Neuroscience, Inc.	- USD	-Infinity%
Annovis Bio, Inc.	- USD	-Infinity%
Biohaven Pharmaceutical Holding Company Ltd.	- USD	-Infinity%
Ginkgo Bioworks Holdings, Inc.	251.45 Million USD	72.338%
Nuvation Bio Inc.	- USD	-Infinity%
Nuvation Bio Inc.	- USD	-Infinity%
Arcus Biosciences, Inc.	117 Million USD	40.549%
Zymeworks Inc.	76.01 Million USD	8.491%